Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Mar;69(3):e29522.
doi: 10.1002/pbc.29522. Epub 2021 Dec 28.

Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia

Roxana Carmona  1 , Hande Kizilocak  1 , Elizabeth Marquez-Casas  1 , Siobhan Vasquez  1 , Lingyun Ji  2 , Richard H Ko  1   3 , Guy Young  1   3 , Julie Jaffray  1   3
Affiliations

Markers of hypercoagulability in children with newly diagnosed acute lymphoblastic leukemia

Roxana Carmona et al. Pediatr Blood Cancer. 2022 Mar.

Abstract

Background: Venous thromboembolism (VTE) is a known complication for children with acute lymphoblastic leukemia (ALL). The aim of this study was to identify laboratory biomarkers that predict which children with ALL are at risk for VTE during induction chemotherapy.

Materials and methods: Newly diagnosed ALL patients admitted to Children's Hospital Los Angeles with a central venous catheter (CVC) were eligible to participate. Participants' blood samples (complete blood count [CBC], quantitative D-dimer, prothrombin fragment 1.2 [PTF 1.2], and thrombin-antithrombin complexes [TAT]) were collected at day 0 (baseline/prior to induction), day 7 (±2 days), day 14 (±2 days), day 21 (±2 days), and day 28 (±2 days) of induction chemotherapy or until participants presented with a symptomatic VTE.

Results: Seventy-five participants aged 1-21 years were enrolled and included in the final analysis. Twenty-six (35%) of the 75 participants were diagnosed with a CVC-associated VTE (22 asymptomatic and four symptomatic). There was a statistically significant difference between VTE and non-VTE participants for D-dimer (odds ratio [OR] 1.61, 95% confidence interval [CI]: 1.59-1.64), TAT (OR 1.34, 95% CI: 1.32-1.38), and PTF 1.2 (OR 1.31, 95% CI: 1.25-1.37) at all time points. Participants >10 years had a significantly higher risk of developing a VTE compared to participants <4 years (p = .007).

Conclusion: Older children with ALL as well as those with an elevated TAT, PTF 1.2, or D-dimer showed an increased risk of VTE, which may hold potential for predicting VTE in future studies.

Keywords: acute lymphoblastic leukemia; hypercoagulability; pediatrics; venous thromboembolism.

PubMed Disclaimer

References

REFERENCES

    1. Kizilocak H, Okcu F. Late effects of therapy in childhood acute lymphoblastic leukemia survivors. Turk J Haematol. 2019;36:1-11. https://doi.org/10.4274/tjh.galenos.2018.2018.0150
    1. Jaffray J, Goldenberg N. Current approaches in the treatment of catheter-related deep venous thrombosis in children. Expert Rev Hematol. 2020;13:607-617.
    1. Levy-Mendelovich S, Barg AA, Kenet G. Thrombosis in pediatric patients with leukemia. Thromb Res. 2018;164:94-97.
    1. Athale UH, Chan AK. Thrombosis in children with acute lymphoblastic leukemia: part I. Epidemiology of thrombosis in children with acute lymphoblastic leukemia. Thromb Res. 2003;111:125-131.
    1. Mitchell LG, Andrew M, Hanna K, et al. A prospective cohort study determining the prevalence of thrombotic events in children with acute lymphoblastic leukemia and a central venous line who are treated with L-asparaginase: results of the Prophylactic Antithrombin Replacement in Kids with Acute Lymphoblastic Leukemia Treated with Asparaginase (PARKAA) Study. Cancer. 2003;97:508-516.

MeSH terms

LinkOut - more resources